NASDAQ:NEO - NeoGenomics Stock Price, Forecast & News

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics, Inc. (NASDAQ:NEO) released its earnings results on Tuesday, October, 29th. The medical research company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.06 by $0.01. The medical research company had revenue of $104.70 million for the quarter, compared to the consensus estimate of $99.38 million. NeoGenomics had a net margin of 0.55% and a return on equity of 4.60%. The company's quarterly revenue was up 51.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.05 earnings per share. View NeoGenomics' Earnings History.

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for NeoGenomics.

6 analysts have issued 1-year target prices for NeoGenomics' stock. Their forecasts range from $15.00 to $30.00. On average, they expect NeoGenomics' stock price to reach $25.60 in the next year. This suggests that the stock has a possible downside of 4.4%. View Analyst Price Targets for NeoGenomics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.

News coverage about NEO stock has trended somewhat negative on Thursday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. NeoGenomics earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for NeoGenomics.

NeoGenomics saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 6,450,000 shares, an increase of 14.4% from the September 30th total of 5,640,000 shares. Based on an average trading volume of 770,800 shares, the short-interest ratio is presently 8.4 days. Currently, 6.5% of the company's stock are short sold. View NeoGenomics' Current Options Chain.

Some companies that are related to NeoGenomics include Teva Pharmaceutical Industries (TEVA), West Pharmaceutical Services (WST), Bio-Rad Laboratories (BIO), Avantor (AVTR), Neurocrine Biosciences (NBIX), Bausch Health Companies (BHC), Bio-Rad Laboratories (BIO.B), Henry Schein (HSIC), Carl Zeiss Meditec (AFX), Elanco Animal Health (ELAN), Eurofins Scientific (ERFSF), Mylan (MYL), Ono Pharmaceutical (OPHLF), Canopy Growth (WEED) and Qiagen (QGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), Intel (INTC), Netflix (NFLX), AbbVie (ABBV), CVS Health (CVS), Exelixis (EXEL) and AT&T (T).

NeoGenomics' stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (2.59%), Eagle Asset Management Inc. (2.59%), Emerald Mutual Fund Advisers Trust (1.71%), Emerald Advisers LLC (1.67%), Granahan Investment Management Inc. MA (0.94%) and Russell Investments Group Ltd. (0.55%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics.

NEO stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Castleark Management LLC, Rice Hall James & Associates LLC, First Trust Advisors LP, Gabelli Funds LLC, Robeco Institutional Asset Management B.V. and Russell Investments Group Ltd.. Company insiders that have sold NeoGenomics company stock in the last year include Electric Co General, George Cardoza, Jennifer Balliet, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View Insider Buying and Selling for NeoGenomics.

NEO stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Street Corp, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, New York State Teachers Retirement System, Squarepoint Ops LLC, Granahan Investment Management Inc. MA and State of Alaska Department of Revenue. View Insider Buying and Selling for NeoGenomics.

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NEO stock can currently be purchased for approximately $26.78.

NeoGenomics has a market capitalization of $2.80 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics.

The official website for NeoGenomics is http://www.neogenomics.com/.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]